McMinn Rachel
Chief Executive Officer at NGNE; Chief Strategy Officer at INTERCEPT PHARMACEUTICALS INC
- Sold, on record
- $615k
- Dollars the filings state
- Form 4 sales
- 17
- Latest Mar 26, 2026
- Form 144 notices
- 0
- Proposed sales
- Companies
- 2
- Filed as an executive or holder
Companies
- NGNENeurogene Inc.Chief Executive Officer
- INTERCEPT PHARMACEUTICALS INCChief Strategy Officer
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- INTERCEPT PHARMACEUTICALS INC3,803 shares
- NGNE3,352 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale INTERCEPT PHARMACEUTICALS INCPlan not statedOct 31, 2016 2016
Sold 129 shares at $123.82 ($16k)
McMinn Rachel, Chief Strategy Officer
Sold 0.9% of holdings ($1.7M position)13,732 shares left1x usual sizeFiling
- 2 Form 4 sale INTERCEPT PHARMACEUTICALS INCUnusualJan 3, 2017 +64 days
Sold 816 shares at $103.92 ($85k)
McMinn Rachel, Chief Strategy Officer
Sold 5.9% of holdings ($1.4M position)12,916 shares left6.4x usual sizeFiling
- 3 Form 4 sale INTERCEPT PHARMACEUTICALS INCPlan not statedApr 3, 2017 +90 days
Sold 257 shares at $115.00 ($30k)
McMinn Rachel, Chief Strategy Officer
Sold 1.4% of holdings ($2.1M position)17,659 shares left2x usual sizeFiling
- 4 Form 4 sale INTERCEPT PHARMACEUTICALS INCPlan not statedMay 1, 2017 +28 days
Sold 114 shares at $113.12 ($13k)
McMinn Rachel, Chief Strategy Officer
Sold 0.6% of holdings ($2M position)17,545 shares left0.9x usual sizeFiling
- 5 Form 4 sale INTERCEPT PHARMACEUTICALS INCPlan not statedJul 3, 2017 +63 days
Sold 257 shares at $121.78 ($31k)
McMinn Rachel, Chief Strategy Officer
Sold 1.5% of holdings ($2.1M position)17,288 shares left2x usual sizeFiling
- 6 Form 4 sale INTERCEPT PHARMACEUTICALS INCPlan not statedJul 31, 2017 +28 days
Sold 130 shares at $123.12 ($16k)
McMinn Rachel, Chief Strategy Officer
Sold 0.8% of holdings ($2.1M position)17,158 shares left1x usual sizeFiling
- 7 Form 4 sale INTERCEPT PHARMACEUTICALS INCPlan not statedOct 2, 2017 +63 days
Sold 283 shares at $58.89 ($17k)
McMinn Rachel, Chief Strategy Officer
Sold 1.6% of holdings ($1M position)16,875 shares left2.2x usual sizeFiling
- 8 Form 4 sale NGNERoutineMar 26, 2026 +3097 days
Sold 3,352 shares at $22.07 ($74k)
McMinn Rachel, Chief Executive Officer
10b5-1 planSold 0.2% of holdings ($29.7M position)1.3M shares leftFirst sale on recordFiling
Every transaction
Loading transactions…
Sales and notices (17)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Mar 26, 2026 | Mar 30, 2026 | NGNE | Chief Executive Officer | Form 4 sale | 3,352 | $74k | 0.2% | Routine | SEC |
| Oct 2, 2017 | Oct 4, 2017 | INTERCEPT PHARMACEUTICALS INC | Chief Strategy Officer | Form 4 sale | 283 | $17k | 1.6% | Plan not stated | SEC |
| Jul 31, 2017 | Aug 2, 2017 | INTERCEPT PHARMACEUTICALS INC | Chief Strategy Officer | Form 4 sale | 130 | $16k | 0.8% | Plan not stated | SEC |
| Jul 3, 2017 | Jul 5, 2017 | INTERCEPT PHARMACEUTICALS INC | Chief Strategy Officer | Form 4 sale | 257 | $31k | 1.5% | Plan not stated | SEC |
| May 1, 2017 | May 3, 2017 | INTERCEPT PHARMACEUTICALS INC | Chief Strategy Officer | Form 4 sale | 114 | $13k | 0.6% | Plan not stated | SEC |
| Apr 3, 2017 | Apr 5, 2017 | INTERCEPT PHARMACEUTICALS INC | Chief Strategy Officer | Form 4 sale | 257 | $30k | 1.4% | Plan not stated | SEC |
| Jan 3, 2017 | Jan 5, 2017 | INTERCEPT PHARMACEUTICALS INC | Chief Strategy Officer | Form 4 sale | 816 | $85k | 5.9% | Unusual | SEC |
| Oct 31, 2016 | Nov 2, 2016 | INTERCEPT PHARMACEUTICALS INC | Chief Strategy Officer | Form 4 sale | 129 | $16k | 0.9% | Plan not stated | SEC |
| Aug 1, 2016 | Aug 2, 2016 | INTERCEPT PHARMACEUTICALS INC | Chief Strategy Officer | Form 4 sale | 125 | $22k | 0.9% | Plan not stated | SEC |
| Jul 5, 2016 | Jul 7, 2016 | INTERCEPT PHARMACEUTICALS INC | Chief Strategy Officer | Form 4 sale | 106 | $15k | 0.8% | Plan not stated | SEC |
| May 2, 2016 | May 4, 2016 | INTERCEPT PHARMACEUTICALS INC | Chief Strategy Officer | Form 4 sale | 130 | $19k | 0.9% | Plan not stated | SEC |
| Apr 4, 2016 | Apr 6, 2016 | INTERCEPT PHARMACEUTICALS INC | Chief Strategy Officer | Form 4 sale | 104 | $14k | 0.7% | Plan not stated | SEC |
| Feb 1, 2016 | Feb 3, 2016 | INTERCEPT PHARMACEUTICALS INC | Chief Strategy Officer | Form 4 sale | 128 | $13k | 1.7% | Plan not stated | SEC |
| Jan 4, 2016 | Jan 5, 2016 | INTERCEPT PHARMACEUTICALS INC | Chief Strategy Officer | Form 4 sale | 469 | $68k | 5.7% | Unusual | SEC |
| Nov 2, 2015 | Nov 4, 2015 | INTERCEPT PHARMACEUTICALS INC | Chief Strategy Officer | Form 4 sale | 125 | $20k | 1.5% | Plan not stated | SEC |
| Jul 31, 2015 | Aug 4, 2015 | INTERCEPT PHARMACEUTICALS INC | Chief Strategy Officer | Form 4 sale | 127 | $33k | 2.9% | Plan not stated | SEC |
| May 1, 2015 | Jul 17, 2015 | INTERCEPT PHARMACEUTICALS INC | Chief Strategy Officer | Form 4 sale | 503 | $128k | 10.2% | Plan not stated | SEC |